If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Valter Torri is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
  • Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

    Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 31 others, La Verde, N., Bianchi, G. V., Artale, S., Blasi, L., De Laurentiis, M., Atzori, F., Turletti, A., Porpiglia, M., Santini, D., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Giordano, M., Donadio, M., Biganzoli, L., Del Mastro, L., Bisagni, G., Livi, L., Natoli, C., Montemurro, F., Riccardi, F., Romagnoli, E., Marchetti, P., Torri, V., Pronzato, P. & Mustacchi, G., Jan 1 2020, In : Breast Care. 15, p. 30-37 8 p.

    Research output: Contribution to journalArticle

  • Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade

    Russo, G. L., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., Milione, M., Porcu, L., Proto, C., Pruneri, G., Signorelli, D., Sangaletti, S., Sfondrini, L., Storti, C., Tassi, E., Bardelli, A. & 9 others, Marsoni, S., Torri, V., Tripodo, C., Colombo, M. P., Anichini, A., Rivoltini, L., Balsari, A., Sozzi, G. & Garassino, M. C., 2019, In : Clinical Cancer Research. 25, 3, p. 989-999 11 p.

    Research output: Contribution to journalArticle

    Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

    Proto, C., Ferrara, R., Signorelli, D., Lo Russo, G., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., De Simone, I., Colombo, M. P., Sica, A., Torri, V. & Garassino, M. C., May 2019, In : Cancer Treatment Reviews. 75, p. 39-51 13 p.

    Research output: Contribution to journalArticle

  • Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

    Proto, C., Ferrara, R., Signorelli, D., Lo Russo, G., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., De Simone, I., Colombo, M. P., Sica, A., Torri, V. & Garassino, M. C., May 2019, In : Cancer Treatment Reviews. 75, p. 39-51 13 p.

    Research output: Contribution to journalReview article